Contact:
Carrie Munk
The ALS Association
(571) 319-3047
cmunk@alsa-national.org

 

FOR IMMEDIATE RELEASE

Insights into Gene Changes in Different Forms of ALS

Washington, D.C. (July 20, 2015) — Research funded by The ALS Association has begun to reveal the wide range of cellular changes brought about by the most common genetic cause of ALS. The research also shows that sporadic (non-familial) ALS is characterized by fewer changes, and in largely different genes, adding to the growing understanding of the cellular basis of ALS and providing insights for pursuit of new treatments.

ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and no life-prolonging treatments for the disease. 

The study examined changes in transcription, or “reading,” of genes throughout the genome caused by the C9orf72 gene mutation, which accounts for up to 40% of familial ALS and up to 6% of sporadic disease. The study also looked at transcription changes in sporadic ALS not due to any known genes. The researchers found that the C9orf72 mutation caused changes in transcription of hundreds of genes in both the frontal cortex and the cerebellum, two regions affected by the disease. There were fewer changes in sporadic ALS. Relatively few of the affected genes overlapped between the two forms of the disease, pointing out the distinct nature of different types of ALS. In both cases, the changes seen included alterations in the processing of RNA, the “working copy” of a gene, further strengthening the hypothesis that changes in RNA processing are central to the disease process in multiple forms of ALS.

“This important work sheds new light on exactly how the ALS disease process occurs in both an important genetic form and in sporadic disease,” said Lucie Bruijn, Ph.D., M.B.A., Chief Scientist for The ALS Association. “The specific genes uncovered by this study can now be examined in more detail to determine which of them might point toward an effective therapy to interrupt the disease process.”

Powered by Blackbaud
nonprofit software